Our sector specialties include: Consumer; Healthcare; Media; Power & Energy Transition; and Technology. Guggenheim Equity Research analysts average 18 years of Wall Street and industry experience, bringing our clients rich perspectives and deep domain expertise.
Rigorous primary research is central to our approach. Innovation and disruption are constants in the sectors we cover and on-the-ground work keeps our team at the leading edge of trend changes for the benefit of our clients. Our signature research products uncover these findings and include:
The Consumer team covers automotive, e-commerce, hardline and softline retail, and restaurants.
The Healthcare team covers biotechnology, biopharmaceuticals, diagnostics and life sciences tools, and healthcare services.
The Power & Energy Transition team covers energy & industrial technology, power, and utilities.
For access to our research offerings and products, please contact your Guggenheim Securities Sales representative or email GSInfo@guggenheimpartners.com.
Already Registered? View the content library on the research portal (login required).
I&I Spotlight Series – Treg-based Therapies
Senior Managing Directors Whitney Wolfe and Yatin Suneja partake in a Q&A session regarding the future of the Treg-Therapies.
Highlights From the Second Guggenheim Targeted Protein Day
Senior Managing Director Michael Schmidt discusses the key topics from the event.
Date | Sector | Location | Conference Name |
---|---|---|---|
6/24-6/27 | Healthcare | Boston | Guggenheim BioFrontier Boston |
Guggenheim Thanks Participants and Attendees of LA Bus Tour
Guggenheim Securities Equity Research would like to thank the participants and attendees of the firm's Los Angeles Bus Tour, hosted by Entertainment & Digital Media Equity Research Analyst Michael Morris. The firm hosted meetings with executives from notable media companies between May 27-28.
Ron Jewsikow's Research Featured in Barron's
Automotive Equity Research Analyst Ron Jewsikow's research was featured in a Barron's article that focused on his analysis of the per-unit tariff costs for more than a dozen automobile manufacturers. The article highlighted the companies that Jewsikow believes are best-positioned to weather tariff-related headwinds.
Vamil Divan Joins Yahoo Finance and Bloomberg to Discuss Pharmaceutical Industry
Global Biopharmaceuticals and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA joined Yahoo Finance and Bloomberg Television to discuss strategic opportunities for one of the world's largest pharmaceutical companies.